B+
Bull case
20%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
AKTX
Akari TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Q2 update adds financing capacity, advancing IND-enabling work, positive preclinical data, and a strategic collaboration. Successful execution toward a mid-2027 Phase 1 start could materially re-rate the stock.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
AKTX-101 remains preclinical and depends on successful IND-enabling, manufacturing, regulatory, and clinical execution.
Momentum
40
Value
42
Sentiment
19
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.00 · Bull $12.00 · Bear $3.00Analysis 2026-08-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $28.50
Why
Momentum40 · Δ7d -61.7
Value42 · Δ7d -0.0
Sentiment19 · Δ7d -30.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • AKTX-101 remains preclinical and depends on successful IND-enabling, manufacturing, regulatory, and clinical execution.
- • Financing and warrant activity can create dilution and elevated micro-cap volatility.
- • AKTX remains a low-coverage, preclinical micro-cap biotech with no clinical efficacy data.
Catalyst clock
2026-08-13
Q2 2026 update and financing support
Lead driver: Value · See fundamentals
Momentum
40
9% active weight
Current posture
7d trendSoftening
Δ7d
-61.7
Δ21d
-
Value
42
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
19
62% active weight
Current posture
7d trendSoftening
Δ7d
-30.6
Δ21d
-
Why this grade
Composite grade F. Momentum 39.8 / Value 41.9 / Sentiment 18.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-14. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$13.16M
Beta
0.36
Shares Out
1.75M
P/E (TTM)
-
P/S (TTM)
-
P/FCF (TTM) · Derived
-21.59
Rev YoY
-
EPS YoY
+16.7%
Gross Margin
-
Op Margin
-
Net Debt
-$4.51M
Current Ratio
0.60
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data